Abrégé

The present disclosure relates to a process for preparing a compound of formula (7), comprising the step of reacting a compound of formula (6) with a reducing agent, and to process for preparing deoxycholic acid or a pharmaceutically acceptable salt thereof comprising said step, and to uses of the deoxycholic acid or a pharmaceutically acceptable salt thereof prepared by the process to extract outer membrane vesicles from Gram-negative bacteria.

Produits et services

Pharmaceutical preparations for use in immunology; Pharmaceutical preparations for the treatment and prevention of inflammatory diseases and disorders; Antibodies for medical purposes; Pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders; Vaccines for human use

Abrégé

Methods and uses of conjugating saccharides to protein carriers are disclosed herein. Exemplary conjugates prepared according to those methods and uses are also disclosed. Additionally, methods for quantifying the amount of sodium borohydride in a sodium cyanoborohydride reagent are disclosed herein. Vaccine compositions as well as related methods and uses are also disclosed herein.

Classes IPC  ?

• A61K 39/095 - Neisseria
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/09 - Streptococcus
• A61K 39/102 - PasteurellaHaemophilus
• A61K 39/385 - Haptènes ou antigènes, liés à des supports
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• G01N 24/08 - Recherche ou analyse des matériaux par l'utilisation de la résonance magnétique nucléaire, de la résonance paramagnétique électronique ou d'autres effets de spin en utilisant la résonance magnétique nucléaire

Produits et services

Pharmaceutical products; vaccines.

Produits et services

(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, pharmaceutical preparations for use in inflammatory, antibodies for medical use; pharmaceutical product for the prevention and treatment of respiratory diseases and disorders, vaccines for human use

Abrégé

The present disclosure provides for circular RNA (circRNA) compositions and methods purification and use of the same. In particular, the disclosure relates to compositions and methods of making and using circRNA comprising one or more aptamers which specifically bind an affinity ligand.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider

Abrégé

This application relates to modified RNA polymerases, compositions or kits comprising the same, and methods of using the same, in particular, in the preparation of ribonucleic acids (RNAs), such as messenger RNAs (mRNAs), in in vitro transcription reactions.

Classes IPC  ?

• C12N 9/10 - Transférases (2.)
• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
• C12N 15/09 - Technologie d'ADN recombinant
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• A61K 38/45 - Transférases (2)
• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
• C40B 40/08 - Bibliothèques comprenant de l'ARN ou de l'ADN codant des protéines, p. ex. bibliothèques de gènes

Abrégé

A discrete-data object is received and may include a plurality of first discrete values, the discrete-data object may include one or more amino acid sequences. The discrete-data object is converted into a continuous-data object that may include a plurality of first continuous values. To the continuous-data object, a continuous-data algorithm is applied to generate a continuous-result object that may include a plurality of second continuous values. The continuous-result object is converted into a discrete-result object which may include a plurality of second discrete values. A vaccine is manufactured which may include at least one of the group that may include i) a protein defined by the discrete-result object, ii) a nucleic acid capable of producing the protein defined by the discrete-result object, and iii) a delivery vehicle capable of producing the protein defined by the discrete-result object.

Classes IPC  ?

• G16B 15/30 - Ciblage de médicament à l’aide de données structurellesPrévision d’amarrage ou de liaison moléculaire
• G16B 40/20 - Analyse de données supervisée

Abrégé

One or more data objects are received defining a plurality of wild-type amino acid sequences. From the one or more data objects, a plurality of reduced-dimension sequences are generated in a reduced-dimension space. A plurality of candidate sequences are generated in the reduced-dimension space using the plurality of reduced-dimension sequences. One or more data objects defining a viral amino acid sequence are received. Viral sequences in the reduced-dimension space are received. As input to a titer-predictor, each of the candidate sequences and at least one of the reduced-dimension viral sequences are provided. As output from the titer-predictor, a candidate-score for each of the candidate sequences is received. At least one candidate sequence from among the candidate sequences are selected. At least one new amino acid sequence is generated. Each of the generated amino acid sequences is suitable for manufacturing a respective vaccine.

Classes IPC  ?

• G16B 40/00 - TIC spécialement adaptées aux biostatistiquesTIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p. ex. extraction de connaissances ou détection de motifs

Produits et services

Pharmaceutical preparations for the prevention of influenza; Vaccines; Vaccines against flu

Abrégé

Stable liquid, lyophilized, and frozen formulations are provided for live-attenuated and/or vector-based vaccines.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 31/22 - Antiviraux pour le traitement des virus ADN des virus de l'herpès
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

Provided herein is a nucleic acid (e.g., messenger RNA) vaccine encoding at least one antigenic prokaryotic polypeptide linked to one or both of a viral secretion signal peptide and a transmembrane domain. Also provided are methods of vaccination against a prokaryotic infection with the nucleic acid described herein.

Classes IPC  ?

• A61K 39/02 - Antigènes bactériens
• A61K 9/1272 - Liposomes non conventionnels, p. ex. liposomes modifiés par un PEG ou liposomes enduits de ou greffés avec des polymères comprenant des agents tensioactifs non phosphatidyliques comme substances formant des bicouches, p. ex. lipides cationiques ou liposomes non phosphatidyliques enduits de ou greffés avec des polymères
• A61K 9/51 - Nanocapsules
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 39/165 - Virus des oreillons ou de la rougeole
• A61K 39/20 - Virus de la rubéole
• A61K 39/205 - Rabdoviridae, p. ex. virus de la rage
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 39/25 - Herpesvirus varicellae
• A61K 39/285 - Virus de la vaccine ou virus de la variole
• A61P 31/04 - Agents antibactériens
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques

Abrégé

The disclosure relates to methods for detecting at least a first mRNA and a second mRNA or two or more mRNAs in a multi-mRNA composition using reverse-phase high pressure liquid chromatography (RP-HPLC). The methods are particularly suitable for analyzing multi- mRNA compositions comprising first and second mRNAs or two or more mRNAs of similar lengths. The disclosed methods also find utility in assessing the quality and/or integrity of each of the at least first and second mRNAs or two or more mRNAs in a multi-mRNA composition. In addition, the disclosed methods can be used to calculate the proportion of each mRNA in a multi-mRNA composition.

Classes IPC  ?

• G01N 30/34 - Contrôle des paramètres physiques du fluide vecteur de la composition du fluide, p. ex. du gradient
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• G01N 30/88 - Systèmes intégrés d'analyse, spécialement adaptés à cet effet, non couverts par un seul des groupes
• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres

Abrégé

Provided herein are compounds, compositions, formulations, kits, uses, and methods for vaccinating a subject against Neisseria meningitidis.

Classes IPC  ?

• A61K 39/095 - Neisseria
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p. ex. séquences de liaison peptidiques vulnérable aux protéases

Produits et services

(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use

Produits et services

(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use

Produits et services

(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use

Produits et services

(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use

Produits et services

(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use

Produits et services

(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use

Produits et services

(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use

Produits et services

(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use

Produits et services

(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use

Produits et services

(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use

Produits et services

(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use

Abrégé

The disclosure relates to lipidic compounds of formula (I): A—(CH2)n—CX—B—Z—R1 (I) wherein R1 represents a lipophilic or hydrophobic tail-group, wherein RI is an optionally substituted, branched, saturated or unsaturated, C10 to C55 hydrocarbon radical, and which hydrocarbon skeleton that is optionally interrupted by one or several atoms of oxygen or nitrogen and/or one or several moiety —(C═O)—, —O—(C═O)— or —(C═O)—O— and which one nitrogen atom, if present in the skeleton, can be linked, directly or not, to said Z radical; Z is a spacer arm; B represents O or NH; X is O or S; n is 0, 1, 2, 3, 4, 5 or 6; and A represents (i) R2R3N-, (ii) NR2R3-Alk-Y-in which Y is O or N, Alk is an alkylene moiety in C2 to C6 and R2 and R3 represent independently of each other a linear or branched (C1-C6) alkyl group, or (iii) a 4- to 8-membered saturated heterocyclic radical comprising 3 to 7 carbon atoms and 1 or 2 nitrogen atoms, said 4- to 8-membered saturated heterocyclic radical being linked to the rest of the molecule by a carbon atom or a nitrogen atom and being optionally substituted by 1 to 4 substituents, independently of each other, selected from a linear or branched (C1-C6) alkyl group; or one of its pharmaceutically acceptable salts thereof; and with said compound that is in all the possible racemic, enantiomeric and diastereoisomeric isomer forms.

Classes IPC  ?

• A61K 9/1272 - Liposomes non conventionnels, p. ex. liposomes modifiés par un PEG ou liposomes enduits de ou greffés avec des polymères comprenant des agents tensioactifs non phosphatidyliques comme substances formant des bicouches, p. ex. lipides cationiques ou liposomes non phosphatidyliques enduits de ou greffés avec des polymères
• A61K 9/51 - Nanocapsules
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
• C07C 229/12 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant un seul groupe amino et un seul groupe carboxyle liés au squelette carboné l'atome d'azote du groupe amino étant lié de plus à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons à des atomes de carbone de squelettes carbonés acycliques
• C07C 237/08 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant les atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques du squelette carboné le squelette carboné étant acyclique et saturé ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone acyclique d'un radical hydrocarboné substitué par des atomes d'oxygène liés par des liaisons simples
• C07D 207/16 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
• C07D 211/34 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
• C07D 211/62 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile liés en position 4
• C07D 295/15 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec les atomes d'azote du cycle et les atomes de carbone comportant trois liaisons à des hétéro-atomes liés à la même chaîne carbonée, qui n'est pas interrompue par des carbocycles à une chaîne acyclique saturée

Abrégé

Provided herein are methods of purifying messenger RNA (mRNA) by subjecting a preparation comprising in vitro synthesized mRNA to one or more steps of enzymatic digestion with a proteinase, optionally with a further oligo dT affinity chromatography step. Also provided are mRNA purified by the methods described herein.

Classes IPC  ?

• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN

Abrégé

Provided herein are methods of purifying messenger RNA (mRNA) by subjecting a preparation comprising in vitro synthesized mRNA to one or more steps of enzymatic digestion with a proteinase, optionally with a further oligo dT affinity chromatography step. Also provided are mRNA purified by the methods described herein.

Classes IPC  ?

• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN

Abrégé

This application relates to modified influenza B hemagglutinin polypeptides and nucleic acids, such as messenger ribonucleic acids (mRNAs), encoding the same, as well as compositions comprising the same, vaccines comprising the same, and methods of using the same, such as in the prevention and/or treatment of diseases or conditions caused by influenza B viruses.

Classes IPC  ?

• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61P 37/04 - Immunostimulants
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus

Produits et services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use

Produits et services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use

Produits et services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use

Produits et services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use

Produits et services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use

Produits et services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use

Produits et services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use

Produits et services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use

Produits et services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use

Produits et services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use

Produits et services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use

Produits et services

Pharmaceutical products; vaccines.

Produits et services

Pharmaceutical products; vaccines.

Produits et services

Pharmaceutical products; vaccines.

Produits et services

Pharmaceutical products; vaccines.

Produits et services

Pharmaceutical products; vaccines.

Produits et services

Pharmaceutical products; vaccines.

Produits et services

Pharmaceutical products; vaccines.

Produits et services

Pharmaceutical products; vaccines.

Produits et services

Pharmaceutical products; vaccines.

Produits et services

Pharmaceutical products; vaccines.

Produits et services

Pharmaceutical products; vaccines.

Abrégé

The present disclosure provides a Lyme disease vaccine, comprising a messenger RNA (mRNA) comprising an open reading frame (ORF) encoding at least one antigenic polypeptide derived from at least one bacteria of the genus Borrelia, and methods of eliciting an immune response by administering said vaccine.

Classes IPC  ?

• A61K 39/02 - Antigènes bactériens
• A61K 9/50 - Microcapsules
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 37/04 - Immunostimulants

Abrégé

The present disclosure provides compositions comprising at least two messenger RNAs (mRNAs) consisting of a human respiratory syncytial virus (hRSV or RSV) F protein antigen, a human metapneumovirus (hMPV) F protein antigen, and/or a human parainfluenza virus 3 (hPIV3 or PIV3) F protein antigen, and methods of eliciting an immune response by administering said compositions.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61K 9/50 - Microcapsules
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 37/04 - Immunostimulants

Abrégé

The present disclosure provides a human metapneumovirus (hMPV) vaccine comprising an hMPV F protein antigen, and methods of eliciting an immune response by administering said vaccine.

Classes IPC  ?

• A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12N 15/86 - Vecteurs viraux

Abrégé

The present disclosure relates to an immunogenic composition comprising a combination of meningococcal antigens which comprises at least one factor H binding protein (fHBP) A protein, at least one fHBP B protein, at least one Neisseria adhesin A (NadA) protein, and at least one detergent-extracted Outer Membrane Vesicle (dOMV). The meningococcal antigens may be from a Neisseria meningitidis serogroup B. The combination of antigens provided a broad coverage of bacteria strains. Further, the present disclosure relates to the use of the immunogenic composition in methods for eliciting an immune response.

Classes IPC  ?

• A61K 39/095 - Neisseria
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 31/04 - Agents antibactériens
• A61P 37/04 - Immunostimulants

Abrégé

The present invention relates to a method for freezing or freeze-drying lipid nanoparticles (LNPs) comprising at least a nucleic acid and, at least, as lipid components, a cationic ionizable lipid, a neutral lipid, and a steroid alcohol, or an ester thereof. The method comprises the steps of providing a liquid composition comprising said LNPs, spraying the composition of step a) in conditions suitable for obtaining liquid droplets, and freezing the liquid droplets obtained at step b) to obtain frozen LNPs. The method may also comprise a step of drying the frozen LNPs obtained to obtain freeze-dried LNPs. The invention also relates to frozen and freeze-dried LNPs.

Classes IPC  ?

• A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
• A61K 9/51 - Nanocapsules
• A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester

Abrégé

Disclosed herein are respiratory syncytial virus vaccines and methods of immunization to deliver respiratory syncytial virus vaccines in subjects.

Classes IPC  ?

• A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

Abrégé

Systems and devices for filtering biological products and methods of using the same are provided. A filtration system can include a filtration skid configured to be adapted for engagement with components of a single-use assembly for facilitating one or more unit operations of a continuous filtering process for the one or more biological products. The filtration skid can include a pump cart and a filtration cart. The filtration cart can include a first filter support assembly configured to support a first filtering flow channel and a second filter support assembly configured to support a second filtering flow channel.

Classes IPC  ?

• B01D 61/22 - Commande ou régulation
• B01D 65/02 - Nettoyage ou stérilisation de membranes

Produits et services

(1) Pharmaceutical products, vaccines

Produits et services

(1) Pharmaceutical products, vaccines

Produits et services

(1) Pharmaceutical products, vaccines

Produits et services

(1) Pharmaceutical products, vaccines

Produits et services

(1) Pharmaceutical products, vaccines

Produits et services

(1) Pharmaceutical products, vaccines.

Produits et services

(1) Pharmaceutical products, vaccines.

Produits et services

(1) Pharmaceutical products, vaccines.

Produits et services

(1) Pharmaceutical products, vaccines.

Produits et services

(1) Pharmaceutical products, vaccines.

Abrégé

A dose divider for releasable attachment to a plunger rod of a syringe comprises first and second arms. A front portion of the first arm and the front portion of the second arm form a channel therebetween for receiving the plunger rod. A resilient hinge pivotably couples the first arm and the second arm such that the dose divider is reversibly movable between first and second configurations. When the dose divider is in the second configuration, the dose divider is configured to receive the plunger rod in the channel through an opening formed between the front portions of the first and second arms. The channel has a shape configured to receive a specific outer shape of the plunger rod. The front portions of the first and second arms are closer when the dose divider is in the first configuration than when the dose divider is in the second configuration.

Classes IPC  ?

• A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
• A61M 11/00 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux
• A61K 39/12 - Antigènes viraux
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61M 15/00 - Inhalateurs
• A61M 15/08 - Dispositifs d'inhalation placés dans le nez
• B05B 11/02 - Membranes ou pistons agissant sur le contenu à l'intérieur du récipient, p. ex. pistons suiveurs
• F16B 2/22 - Clips, c.-à-d. dispositifs de fixation à serrage effectué uniquement par la résistance à la déformation inhérente au matériau dont est fait le dispositif en matériau élastique, p. ex. un matériau caoutchouteux
• A61M 5/178 - Seringues

Abrégé

This invention relates to compositions (e.g. immunogenic compositions) which can be used to immunise against C. acnes. The compositions comprise C. acnes antigens and antigen combinations, used in the form of nucleic acids (e.g. mRNAs) encoding antigenic proteins or in the form of recombinant protein antigens.

Classes IPC  ?

• A61K 39/05 - CorynebacteriumPropionibacterium
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 37/04 - Immunostimulants
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C07K 14/195 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries

Abrégé

Disclosed herein are respiratory syncytial virus vaccines and methods of immunization to deliver respiratory syncytial virus vaccines in subjects.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

Abrégé

A medicament delivery system comprises a syringe and a plunger rod. The plunger rod comprises a first region of a first outer configuration and a second region of a second outer configuration that is different to the first outer configuration. A blocking element is configured to be provided at a proximal end of the syringe and disposed around the plunger rod, and which permits the plunger rod to move over a first range of motion relative to the syringe to expel a first dose of medicament, and blocks the plunger rod from moving over a subsequent range of motion relative to the syringe to expel further medicament. The blocking element is configured to be removable from the plunger rod. The plunger rod is free to move over the subsequent range of motion relative to the syringe to expel further medicament once the blocking element is removed from the plunger rod.

Classes IPC  ?

• A61M 5/31 - Seringues Parties constitutives
• A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
• A61M 11/00 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux
• A61M 15/08 - Dispositifs d'inhalation placés dans le nez
• A61M 5/178 - Seringues

Abrégé

A delivery system comprises a syringe having a chamber for containing medicament and an outlet through which medicament can be expelled. A plunger rod is moveable relative to the syringe and configured to cause medicament to be expelled from the syringe when medicament is within the syringe and the plunger rod is moved. A disc, when the delivery system is in a first configuration, permits the plunger rod to move over a first range of motion relative to the syringe to expel a first dose of medicament, and blocks the plunger rod from moving over a subsequent range of motion relative to the syringe to expel further medicament. The disc or the plunger rod is rotatable to put the delivery system into a second configuration, in which the plunger rod is free to move over the subsequent range of motion relative to the syringe to expel further medicament

Classes IPC  ?

• A61M 5/31 - Seringues Parties constitutives
• A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
• A61M 11/00 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux
• A61M 15/08 - Dispositifs d'inhalation placés dans le nez
• A61M 5/178 - Seringues

Abrégé

A method of using a dose divider comprising first and second arms, each having a front portion that together form a channel for receiving a syringe plunger rod. A resilient hinge pivotably couples the first and second arms such that the dose divider is reversibly movable between first and second configurations. In the second configuration, the dose divider is configured to receive the plunger rod in the channel formed between the front portions of the first and second arms. The channel is configured to receive a specific outer shape of the plunger rod. The front portions of the first and second arms are closer when the dose divider is in the first configuration than when in the second configuration. The method comprises moving the dose divider from the first configuration to the second configuration by applying a force to the first and second arms such that the first arm pivots in a first direction with respect to the second arm using the resilient hinge.

Classes IPC  ?

• A61M 5/31 - Seringues Parties constitutives
• A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
• A61M 11/00 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux
• A61M 15/08 - Dispositifs d'inhalation placés dans le nez
• A61M 5/178 - Seringues

Abrégé

A medicament delivery system comprises a syringe, a plunger rod is, and a guide element at a proximal end of the syringe and comprising an aperture through which the plunger rod extends. The guide element and the plunger rod are relatively rotatable between blocking and release positions. A guide mechanism provided on the plunger rod and the guide element permits the plunger rod to move axially over a first range of motion relative to the syringe from an initial position to an intermediate position to expel a first dose of medicament, and blocks the plunger rod from moving over a subsequent range of motion relative to the syringe. The plunger rod is free to move in an axial direction over the subsequent range of motion to expel further medicament upon relative rotation of the guide element and the plunger rod from the blocking position to the release position.

Classes IPC  ?

• A61M 5/31 - Seringues Parties constitutives
• A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
• A61M 11/00 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux
• A61K 39/12 - Antigènes viraux
• A61M 15/00 - Inhalateurs
• A61M 15/08 - Dispositifs d'inhalation placés dans le nez
• B05B 11/02 - Membranes ou pistons agissant sur le contenu à l'intérieur du récipient, p. ex. pistons suiveurs
• A61M 5/178 - Seringues

Abrégé

Provided are modified influenza virus subtype 2 neuraminidase molecules lacking all or substantially all of the stalk region that form active, soluble tetrameric neuraminidase when expressed in host cells and vaccine compositions comprising the tetrameric neuraminidase or a nucleic acid encoding the modified monomeric influenza virus subtype 2 neuraminidase molecules that forms tetrameric NA when expressed in a cell. Also provided are methods of using the vaccine compositions to vaccinate or immunize a subject against influenza virus.

Classes IPC  ?

• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 37/04 - Immunostimulants
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)

Abrégé

The present disclosure provides methods and compositions for RNA affinity purification. In particular, the disclosure relates to compositions and methods of making and using mRNA comprising one or more aptamers which specifically bind an affinity ligand.

Classes IPC  ?

• C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN

Abrégé

Disclosed herein are multivalent vaccine or immunogenic compositions comprising one or more recombinant influenza virus hemagglutinin (HA), one or more recombinant influenza virus neuraminidase (NA), and an optional adjuvant. Also disclosed are methods of using the vaccine or immunogenic composition.

Classes IPC  ?

• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 37/04 - Immunostimulants

Abrégé

Disclosed are multivalent vaccine or immunogenic compositions comprising influenza virus hemagglutinin (HA) from standard of care influenza virus strains, or ribonucleic acid molecules encoding the same; and one or more influenza virus HA identified or designed by machine learning, or one or more ribonucleic acid molecules that encode the influenza virus HA identified or designed by machine learning. Also disclosed are methods of using the vaccine or immunogenic compositions.

Classes IPC  ?

• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus

Abrégé

Provided are novel vaccines for prophylactic treatment of SARS-COV-2 infections and COVID-19 and methods of making the vaccines, wherein the vaccines contain an oil-in-water emulsion comprising tocopherol and squalene.

Classes IPC  ?

• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 37/04 - Immunostimulants
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12N 5/07 - Cellules animales ou tissus animaux
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

Produits et services

Pharmaceuticals; vaccines.

Abrégé

Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.

Classes IPC  ?

• A61K 39/09 - Streptococcus
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Produits et services

Pharmaceuticals, namely, pharmaceutical preparations for use in immunology; antibodies for medical use; pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders; vaccines for human use

Produits et services

Pharmaceuticals; Vaccines.

Produits et services

Pharmaceutical preparations, vaccines.

Produits et services

Pharmaceutical preparations, vaccines.

Produits et services

Pharmaceutical preparations, vaccines.

Produits et services

Pharmaceutical preparations, vaccines.

Produits et services

Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use.

Produits et services

Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use.

Produits et services

Pharmaceuticals, namely, pharmaceutical preparations for use in immunology; antibodies for medical use; pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders; vaccines for human use

Produits et services

Pharmaceuticals, namely, pharmaceutical preparations for use in immunology; antibodies for medical use; pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders; vaccines for human use

Produits et services

Pharmaceuticals, namely, pharmaceutical preparations for use in immunology; antibodies for medical use; pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders; vaccines for human use

Produits et services

Pharmaceuticals, namely, pharmaceutical preparations for use in immunology; antibodies for medical use; pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders; vaccines for human use

Produits et services

Pharmaceuticals, namely, pharmaceutical preparations for use in immunology; antibodies for medical use; pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders; vaccines for human use

Produits et services

Pharmaceuticals, namely, pharmaceutical preparations for use in immunology; antibodies for medical use; pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders; vaccines for human use

Produits et services

Pharmaceutical preparations, vaccines.

Produits et services

Pharmaceutical preparations, vaccines.

Produits et services

Pharmaceutical preparations, vaccines.

Produits et services

Pharmaceuticals, namely, pharmaceutical preparations for use in immunology; antibodies for medical use; pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders; vaccines for human use